- Home
- ACHV vs SPAI Comparison
ACHV vs SPAI Comparison
Compare ACHV & SPAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- SPAI
- Stock Information
- Founded
- ACHV N/A
- SPAI 2021
- Country
- ACHV United States
- SPAI United States
- Employees
- ACHV N/A
- SPAI N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SPAI Industrial Specialties
- Sector
- ACHV Health Care
- SPAI Health Care
- Exchange
- ACHV Nasdaq
- SPAI Nasdaq
- Market Cap
- ACHV 153.8M
- SPAI 139.4M
- IPO Year
- ACHV N/A
- SPAI 2024
- Fundamental
- Price
- ACHV $3.15
- SPAI $7.50
- Analyst Decision
- ACHV Strong Buy
- SPAI Strong Buy
- Analyst Count
- ACHV 2
- SPAI 2
- Target Price
- ACHV $16.00
- SPAI $10.50
- AVG Volume (30 Days)
- ACHV 867.2K
- SPAI 369.1K
- Earning Date
- ACHV 11-06-2025
- SPAI 11-13-2025
- Dividend Yield
- ACHV N/A
- SPAI N/A
- EPS Growth
- ACHV N/A
- SPAI N/A
- EPS
- ACHV N/A
- SPAI N/A
- Revenue
- ACHV N/A
- SPAI $1,496,091.00
- Revenue This Year
- ACHV N/A
- SPAI N/A
- Revenue Next Year
- ACHV N/A
- SPAI N/A
- P/E Ratio
- ACHV N/A
- SPAI N/A
- Revenue Growth
- ACHV N/A
- SPAI 7.49
- 52 Week Low
- ACHV $1.84
- SPAI $1.47
- 52 Week High
- ACHV $5.31
- SPAI $9.16
- Technical
- Relative Strength Index (RSI)
- ACHV 56.75
- SPAI 59.63
- Support Level
- ACHV $3.07
- SPAI $6.21
- Resistance Level
- ACHV $3.21
- SPAI $7.50
- Average True Range (ATR)
- ACHV 0.14
- SPAI 0.72
- MACD
- ACHV 0.01
- SPAI -0.09
- Stochastic Oscillator
- ACHV 77.55
- SPAI 72.07
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About SPAI Safe Pro Group Inc. Common Stock
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.